16th August, 2016

Corporate Relationship Department

M/s.BSE Limited
Dalal Street, Fort
Mumbai 400 001
Scrip Code: 524816

Manager Listing
M/s. National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex
Bandra (E) Mumbai 400 051
Scrip Code: NATCOPHARM

Dear Sir
Please find enclose herewith the Press Release for your information.
Thanking you,
Yours faithfully,
For NATCO Pharma Limited
M. Adinarayana
Company Secretary &
Vice President (Legal & Corp. Affairs)

Press Release

Ref:PR/006/2016
NATCO RECEIVES ESTABLISHMENT INSPECTION REPORT
FOR KOTHUR FACILITY
Hyderabad, India, August 16th, 2016

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased announce successful
Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the
inspection conducted at its drug manufacturing facility in Kothur Village, Mahaboob Nagar
District, India, during the period February 29 March 7, 2016. The Kothur facility predominantly
caters to regulated international markets, including USA.
___________________________________________________________________________________
Forwarded for favor of publication
For NATCO Pharma Limited
M. Adinarayana
Company Secretary &
Vice President (Legal and Corp Affairs)